146 related articles for article (PubMed ID: 9541686)
1. A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema.
Villalona-Calero MA; Eckardt J; Burris H; Kraynak M; Fields-Jones S; Bazan C; Lancaster J; Hander T; Goldblum R; Hammond L; Bari A; Drengler R; Rothenberg M; Hadovsky G; Von Hoff DD
Ann Oncol; 1998 Jan; 9(1):71-7. PubMed ID: 9541686
[TBL] [Abstract][Full Text] [Related]
2. Corticotropin-releasing factor decreases vasogenic brain edema.
Tjuvajev J; Uehara H; Desai R; Beattie B; Matei C; Zhou Y; Kreek MJ; Koutcher J; Blasberg R
Cancer Res; 1996 Mar; 56(6):1352-60. PubMed ID: 8640825
[TBL] [Abstract][Full Text] [Related]
3. Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.
Panickar KS
Curr Opin Mol Ther; 2010 Dec; 12(6):780-9. PubMed ID: 21154169
[TBL] [Abstract][Full Text] [Related]
4. Corticorelin acetate injections for the treatment of peritumoral brain edema.
Moliterno JA; Henry E; Pannullo SC
Expert Opin Investig Drugs; 2009 Sep; 18(9):1413-9. PubMed ID: 19678803
[TBL] [Abstract][Full Text] [Related]
5. Comparison of corticotropin-releasing factor, dexamethasone, and temozolomide: treatment efficacy and toxicity in U87 and C6 intracranial gliomas.
Moroz MA; Huang R; Kochetkov T; Shi W; Thaler H; de Stanchina E; Gamez I; Ryan RP; Blasberg RG
Clin Cancer Res; 2011 May; 17(10):3282-92. PubMed ID: 21385926
[TBL] [Abstract][Full Text] [Related]
6. Corticorelin: ACTH RF, corticoliberin, corticotrophin-releasing hormone, corticotropin-releasing factor, human corticotropin-releasing hormone, ovine corticotrophin-releasing factor, Xerecept.
Drugs R D; 2004; 5(4):218-9. PubMed ID: 15230628
[TBL] [Abstract][Full Text] [Related]
7. Treatment of periorbital edema with human corticotropin-releasing factor after blepharoplasty.
Schendel SA; Stephanides M
J Am Coll Surg; 1996 Mar; 182(3):226-32. PubMed ID: 8603242
[TBL] [Abstract][Full Text] [Related]
8. Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion.
Schürmeyer TH; Avgerinos PC; Gold PW; Gallucci WT; Tomai TP; Cutler GB; Loriaux DL; Chrousos GP
J Clin Endocrinol Metab; 1984 Dec; 59(6):1103-8. PubMed ID: 6092407
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans.
Angst MS; Dyck JB; Azarnoff DL; Goldblum R; Ho B; Gfroerer T; Linton EA; Glynn BP; Shafer SL
Clin Pharmacol Ther; 1998 Nov; 64(5):499-510. PubMed ID: 9834042
[TBL] [Abstract][Full Text] [Related]
10. Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway.
Tjuvajev J; Kolesnikov Y; Joshi R; Sherinski J; Koutcher L; Zhou Y; Matei C; Koutcher J; Kreek MJ; Blasberg R
In Vivo; 1998; 12(1):1-10. PubMed ID: 9575420
[TBL] [Abstract][Full Text] [Related]
11. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy.
Recht L; Mechtler LL; Wong ET; O'Connor PC; Rodda BE
J Clin Oncol; 2013 Mar; 31(9):1182-7. PubMed ID: 23382470
[TBL] [Abstract][Full Text] [Related]
12. Corticotropin-releasing factor (CRF): stimulation in normal controls and in patients with Cushing's syndrome.
Müller OA; Hartwimmer J; Hauer A; Kaliebe T; Schopohl J; Stalla GK; von Werder K
Psychoneuroendocrinology; 1986; 11(1):49-60. PubMed ID: 3010360
[TBL] [Abstract][Full Text] [Related]
13. Effects and pharmacokinetic properties of the rat/human corticotropin-releasing factor in rhesus monkeys.
Schürmeyer TH; Gold PW; Gallucci WT; Tomai TP; Cutler GB; Loriaux DL; Chrousos GP
Endocrinology; 1985 Jul; 117(1):300-6. PubMed ID: 2988919
[TBL] [Abstract][Full Text] [Related]
14. The effects of human corticotrophin releasing factor on motor and cognitive deficits after impact acceleration injury.
Beaumont A; Marmarou C; Marmarou A
Neurol Res; 2000 Oct; 22(7):665-73. PubMed ID: 11091970
[TBL] [Abstract][Full Text] [Related]
15. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma.
Lee DK; Fardon TC; Bates CE; Haggart K; McFarlane LC; Lipworth BJ
Chest; 2005 Mar; 127(3):851-60. PubMed ID: 15764767
[TBL] [Abstract][Full Text] [Related]
16. Neuroimaging and quality-of-life outcomes in patients with brain metastasis and peritumoral edema who undergo Gamma Knife surgery.
Pan HC; Sun MH; Chen CC; Chen CJ; Lee CH; Sheehan J
J Neurosurg; 2008 Dec; 109 Suppl():90-8. PubMed ID: 19123894
[TBL] [Abstract][Full Text] [Related]
17. Regional cerebral blood flow in peritumoral brain edema during dexamethasone treatment: a xenon-enhanced computed tomographic study.
Behrens PF; Ostertag CB; Warnke PC
Neurosurgery; 1998 Aug; 43(2):235-40; discussion 240-1. PubMed ID: 9696075
[TBL] [Abstract][Full Text] [Related]
18. Role of hydrodynamic processes in the pathogenesis of peritumoral brain edema in meningiomas.
Bitzer M; Nägele T; Geist-Barth B; Klose U; Grönewäller E; Morgalla M; Heiss E; Voigt K
J Neurosurg; 2000 Oct; 93(4):594-604. PubMed ID: 11014537
[TBL] [Abstract][Full Text] [Related]
19. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial.
Kirste S; Treier M; Wehrle SJ; Becker G; Abdel-Tawab M; Gerbeth K; Hug MJ; Lubrich B; Grosu AL; Momm F
Cancer; 2011 Aug; 117(16):3788-95. PubMed ID: 21287538
[TBL] [Abstract][Full Text] [Related]
20. Simulating vasogenic brain edema using chronic VEGF infusion.
Piazza M; Munasinghe J; Murayi R; Edwards N; Montgomery B; Walbridge S; Merrill M; Chittiboina P
J Neurosurg; 2017 Oct; 127(4):905-916. PubMed ID: 28059647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
